Cantor Fitzgerald Comments on Editas Medicine FY2026 Earnings

Editas Medicine, Inc. (NASDAQ:EDIT) – Stock analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for shares of Editas Medicine in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst E. Schmidt expects that the company will post earnings of ($0.89) per share for the year. Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Editas Medicine’s current full-year earnings is ($2.71) per share.

A number of other analysts have also recently commented on the stock. HC Wainwright initiated coverage on shares of Editas Medicine in a research report on Monday, April 28th. They issued a “buy” rating and a $3.00 price objective for the company. Wall Street Zen raised Editas Medicine from a “sell” rating to a “hold” rating in a research report on Wednesday, May 14th. Finally, Robert W. Baird dropped their price target on Editas Medicine from $8.00 to $4.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 13th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating, two have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $5.36.

Editas Medicine Stock Up 8.8%

EDIT opened at $2.10 on Tuesday. Editas Medicine has a 12 month low of $0.91 and a 12 month high of $6.22. The company has a fifty day simple moving average of $1.50 and a 200 day simple moving average of $1.52. The stock has a market cap of $175.80 million, a P/E ratio of -0.82 and a beta of 2.10.

Editas Medicine (NASDAQ:EDIT) last issued its earnings results on Monday, May 12th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.08. The company had revenue of $4.66 million during the quarter, compared to analysts’ expectations of $0.79 million. Editas Medicine had a negative net margin of 340.96% and a negative return on equity of 80.13%. During the same quarter in the previous year, the company posted ($76.00) EPS.

Insider Activity at Editas Medicine

In related news, CEO Gilmore Neil O’neill sold 15,192 shares of the business’s stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $1.72, for a total value of $26,130.24. Following the completion of the sale, the chief executive officer now directly owns 280,282 shares in the company, valued at $482,085.04. The trade was a 5.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold 16,364 shares of company stock worth $28,146 in the last ninety days. 2.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Editas Medicine

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Invesco Ltd. raised its position in shares of Editas Medicine by 9.2% in the fourth quarter. Invesco Ltd. now owns 100,164 shares of the company’s stock valued at $127,000 after buying an additional 8,448 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of Editas Medicine by 45.9% in the first quarter. Allspring Global Investments Holdings LLC now owns 35,781 shares of the company’s stock valued at $40,000 after buying an additional 11,252 shares in the last quarter. Intech Investment Management LLC raised its position in shares of Editas Medicine by 43.1% in the fourth quarter. Intech Investment Management LLC now owns 40,942 shares of the company’s stock valued at $52,000 after buying an additional 12,336 shares in the last quarter. Dark Forest Capital Management LP raised its position in shares of Editas Medicine by 66.9% in the fourth quarter. Dark Forest Capital Management LP now owns 32,787 shares of the company’s stock valued at $42,000 after buying an additional 13,138 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of Editas Medicine by 2.1% in the fourth quarter. JPMorgan Chase & Co. now owns 787,599 shares of the company’s stock valued at $1,000,000 after buying an additional 16,419 shares in the last quarter. 71.90% of the stock is currently owned by institutional investors and hedge funds.

About Editas Medicine

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.